NZ599204A - High affinity human antibodies to human protease-activated receptor-2 - Google Patents

High affinity human antibodies to human protease-activated receptor-2

Info

Publication number
NZ599204A
NZ599204A NZ599204A NZ59920410A NZ599204A NZ 599204 A NZ599204 A NZ 599204A NZ 599204 A NZ599204 A NZ 599204A NZ 59920410 A NZ59920410 A NZ 59920410A NZ 599204 A NZ599204 A NZ 599204A
Authority
NZ
New Zealand
Prior art keywords
human
human par
seq
ser
par
Prior art date
Application number
NZ599204A
Other languages
English (en)
Inventor
Lynn Macdonald
Andrew J Murphy
Nicholas J Papadopulos
Marc R Morra
Robert R Salzler
Michael L Laccroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of NZ599204A publication Critical patent/NZ599204A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ599204A 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2 NZ599204A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24078309P 2009-09-09 2009-09-09
US24282109P 2009-09-16 2009-09-16
US31783910P 2010-03-26 2010-03-26
PCT/US2010/048034 WO2011031695A1 (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Publications (1)

Publication Number Publication Date
NZ599204A true NZ599204A (en) 2014-05-30

Family

ID=43063654

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599204A NZ599204A (en) 2009-09-09 2010-09-08 High affinity human antibodies to human protease-activated receptor-2

Country Status (29)

Country Link
US (3) US8101724B2 (enExample)
EP (1) EP2475684B1 (enExample)
JP (2) JP5832435B2 (enExample)
KR (1) KR101766701B1 (enExample)
CN (1) CN102574923B (enExample)
AR (1) AR078346A1 (enExample)
AU (1) AU2010292342C1 (enExample)
BR (1) BR112012005338A2 (enExample)
CA (1) CA2773541A1 (enExample)
CY (1) CY1118714T1 (enExample)
DK (1) DK2475684T3 (enExample)
ES (1) ES2609780T3 (enExample)
HR (1) HRP20170324T1 (enExample)
HU (1) HUE031725T2 (enExample)
IL (1) IL218501A (enExample)
JO (1) JO3246B1 (enExample)
LT (1) LT2475684T (enExample)
MX (1) MX2012002927A (enExample)
MY (1) MY159551A (enExample)
NZ (1) NZ599204A (enExample)
PL (1) PL2475684T3 (enExample)
PT (1) PT2475684T (enExample)
SG (1) SG178976A1 (enExample)
SI (1) SI2475684T1 (enExample)
SM (2) SMT201700102T1 (enExample)
TW (1) TWI492757B (enExample)
UY (1) UY32883A (enExample)
WO (1) WO2011031695A1 (enExample)
ZA (1) ZA201201730B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
BR112014006822B1 (pt) * 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
EP3110844B1 (en) * 2014-02-28 2020-02-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP3374386B1 (en) * 2015-11-13 2024-05-29 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
CN118480125A (zh) 2016-11-08 2024-08-13 齐鲁皮吉特湾生物治疗有限公司 抗pd1和抗ctla4抗体
TWI788332B (zh) * 2017-03-16 2023-01-01 英商梅迪繆思有限公司 抗-par2抗體及其用途
JOP20210194A1 (ar) * 2019-01-18 2023-01-30 Janssen Biotech Inc مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
CN114127109B (zh) * 2019-05-30 2022-06-21 山东博安生物技术股份有限公司 靶向Claudin18.2的抗体或嵌合抗原受体
WO2021084760A1 (ja) * 2019-11-01 2021-05-06 株式会社 資生堂 皮膚での活性型ｐａｒ－２を指標とした皮膚状態評価方法、ｐａｒ－２活性化促進剤又は抑制剤のスクリーニング方法及びｐａｒ－２活性化抑制剤
CN113248611A (zh) * 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
EP4126248A4 (en) * 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES
EP4454659A3 (en) 2020-08-18 2025-01-22 Cephalon LLC Anti-par-2 antibodies and methods of use thereof
WO2023034560A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting cd33 and uses thereof
WO2023034564A2 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-cd33 antibodies and uses thereof
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
GB202204159D0 (en) * 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024059336A1 (en) * 2022-09-18 2024-03-21 Memorial Sloan Kettering Cancer Center Inhibition of protease-activated receptor 2 (par2) pathway for treatment and prevention of lymphedema

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874400A (en) 1993-07-26 1999-02-23 Cor Therapeutics Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
WO2008086069A1 (en) * 2007-01-03 2008-07-17 The General Hospital Corporation Methods of treating itch
CL2008001887A1 (es) * 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
KR20090082619A (ko) 2008-01-28 2009-07-31 주식회사 알파크립텍 다프네틴을 함유하는 가려움증 또는 염증 개선용 화장료조성물
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
EP2313110A1 (en) 2008-08-05 2011-04-27 Boehringer Ingelheim International GmbH Effectors of par-2 activation and their use in the modulation of inflammation
CN102458356A (zh) 2009-06-18 2012-05-16 株式会社爱茉莉太平洋 含有栗子皮提取物的化妆料组合物
KR101338681B1 (ko) 2009-06-18 2013-12-09 (주)아모레퍼시픽 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물
FR2947452B1 (fr) 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري

Also Published As

Publication number Publication date
CN102574923B (zh) 2016-12-07
CA2773541A1 (en) 2011-03-17
US20110059095A1 (en) 2011-03-10
DK2475684T3 (en) 2017-03-06
PT2475684T (pt) 2017-02-10
AU2010292342C1 (en) 2015-08-27
US9028819B2 (en) 2015-05-12
HUE031725T2 (en) 2017-08-28
CN102574923A (zh) 2012-07-11
LT2475684T (lt) 2017-01-25
UY32883A (es) 2011-03-31
AR078346A1 (es) 2011-11-02
IL218501A0 (en) 2012-07-31
EP2475684B1 (en) 2016-11-30
AU2010292342B2 (en) 2015-04-30
MY159551A (en) 2017-01-13
SMT201700102T1 (it) 2017-03-08
CY1118714T1 (el) 2017-07-12
SG178976A1 (en) 2012-04-27
IL218501A (en) 2017-03-30
MX2012002927A (es) 2012-08-03
US20120093824A1 (en) 2012-04-19
ES2609780T3 (es) 2017-04-24
WO2011031695A1 (en) 2011-03-17
SI2475684T1 (sl) 2017-03-31
SMT201700102B (it) 2017-03-08
HK1166509A1 (en) 2012-11-02
ZA201201730B (en) 2012-11-28
EP2475684A1 (en) 2012-07-18
US8425907B2 (en) 2013-04-23
US20140179903A1 (en) 2014-06-26
AU2010292342A1 (en) 2012-05-03
TW201121565A (en) 2011-07-01
HRP20170324T1 (hr) 2017-04-21
KR101766701B1 (ko) 2017-08-09
TWI492757B (zh) 2015-07-21
JP6055055B2 (ja) 2016-12-27
KR20120059611A (ko) 2012-06-08
US8101724B2 (en) 2012-01-24
JP5832435B2 (ja) 2015-12-16
PL2475684T3 (pl) 2017-04-28
JP2013504577A (ja) 2013-02-07
JO3246B1 (ar) 2018-03-08
BR112012005338A2 (pt) 2016-11-22
JP2015227381A (ja) 2015-12-17

Similar Documents

Publication Publication Date Title
NZ599204A (en) High affinity human antibodies to human protease-activated receptor-2
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ608660A (en) Anti-cd48 antibodies and uses thereof
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ596295A (en) Anti-5T4 antibodies and uses thereof
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ630433A (en) Antibodies and uses thereof to detect folate receptor 1
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
NZ594682A (en) Fully human antibodies specific to cadm1
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ601583A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
GEP20115324B (en) Tweak binding antibodies
NZ599683A (en) Anti-ilt7 antibody
NZ592151A (en) Anti-igf antibodies
NZ610734A (en) Human antibodies to the glucagon receptor

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 SEP 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20141016

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 SEP 2018 BY ANAQUA SERVICES

Effective date: 20170821

LAPS Patent lapsed